DOT1L Is a Novel Cancer Stem Cell Target for Triple-Negative Breast Cancer
Hetakshi Kurani(University of Miami), Joyce M. Slingerland(University of Miami)
Cited by 71
Related Papers
Exosome Transfer from Stromal to Breast Cancer Cells Regulates Therapy Resistance Pathways
|Cell|2014|798
Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy
|Journal of Clinical Investigation|2011|417
VEGF drives cancer-initiating stem cells through VEGFR-2/Stat3 signaling to upregulate Myc and Sox2
|Oncogene|2014|264
PI3K/mTOR inhibition can impair tumor invasion and metastasis in vivo despite a lack of antiproliferative action in vitro: implications for targeted therapy
|Breast Cancer Research and Treatment|2013|58